240 related articles for article (PubMed ID: 7553634)
21. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
22. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
24. Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.
Schwaab T; Lewis LD; Cole BF; Deo Y; Fanger MW; Wallace P; Guyre PM; Kaufman PA; Heaney JA; Schned AR; Harris RD; Ernstoff MS
J Immunother; 2001; 24(1):79-87. PubMed ID: 11211151
[TBL] [Abstract][Full Text] [Related]
25. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
26. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
27. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.
Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Ernstoff MS; Wells W; Barth R; Deo Y; Fisher J
J Hematother; 1995 Oct; 4(5):471-5. PubMed ID: 8581387
[TBL] [Abstract][Full Text] [Related]
28. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
[TBL] [Abstract][Full Text] [Related]
29. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
[TBL] [Abstract][Full Text] [Related]
30. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
[TBL] [Abstract][Full Text] [Related]
31. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.
Wallace PK; Kaufman PA; Lewis LD; Keler T; Givan AL; Fisher JL; Waugh MG; Wahner AE; Guyre PM; Fanger MW; Ernstoff MS
J Immunol Methods; 2001 Feb; 248(1-2):167-82. PubMed ID: 11223077
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu.
Pullarkat V; Deo Y; Link J; Spears L; Marty V; Curnow R; Groshen S; Gee C; Weber JS
Cancer Immunol Immunother; 1999 Apr; 48(1):9-21. PubMed ID: 10235484
[TBL] [Abstract][Full Text] [Related]
33. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
[TBL] [Abstract][Full Text] [Related]
34. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
[TBL] [Abstract][Full Text] [Related]
36. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
37. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
39. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
[TBL] [Abstract][Full Text] [Related]
40. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
